依鲁替尼治疗慢性淋巴细胞白血病的骨重建 - Suppr

Suppr

超能文献

Bone Reconstruction in Chronic Lymphocytic Leukemia with Ibrutinib.

作者信息

Koba Yusuke, Kawata Takahito, Tamekane Akira, Watanabe Mitsumasa

机构信息

Department of Hematology, Hyogo Prefectural Amagasaki General Medical Center, Japan.

Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Japan.

出版信息

Intern Med. 2023 Sep 15;62(18):2755-2756. doi: 10.2169/internalmedicine.1334-22. Epub 2023 Feb 8.

DOI:10.2169/internalmedicine.1334-22

PMID:36754402

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10569930/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2703/10569930/8a00d1aad757/1349-7235-62-2755-g001.jpg

相似文献

Bone Reconstruction in Chronic Lymphocytic Leukemia with Ibrutinib.

Intern Med. 2023 Sep 15;62(18):2755-2756. doi: 10.2169/internalmedicine.1334-22. Epub 2023 Feb 8.

Prognostic models in chronic lymphocytic leukemia patients receiving ibrutinib therapy: Results of a comparative performance analysis.

Eur J Haematol. 2021 Mar;106(3):425-427. doi: 10.1111/ejh.13548. Epub 2020 Nov 29.

Hepatitis B Virus Reactivation under Ibrutinib Treatment in a Patient with Chronic Lymphocytic Leukemia.

Turk J Haematol. 2020 Aug 28;37(3):208-209. doi: 10.4274/tjh.galenos.2020.2019.0180. Epub 2020 Apr 6.

Ibrutinib as initial therapy in chronic lymphocytic leukemia: A systematic review and meta-analysis.

Eur J Haematol. 2020 May;104(5):512-515. doi: 10.1111/ejh.13387. Epub 2020 Feb 22.

Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study.

Leukemia. 2021 Jan;35(1):235-238. doi: 10.1038/s41375-020-0833-x. Epub 2020 Apr 14.

Intracranial hemorrhage as presentation of chronic lymphocytic leukemia successfully treated with ibrutinib.

Ann Hematol. 2022 Jan;101(1):213-215. doi: 10.1007/s00277-021-04393-3. Epub 2021 Jan 9.

Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes.

Ann Hematol. 2021 Jan;100(1):143-155. doi: 10.1007/s00277-020-04094-3. Epub 2020 Jun 1.

Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia.

Blood. 2021 Feb 25;137(8):1117-1120. doi: 10.1182/blood.2020008608.

Ibrutinib treatment via alternative administration in a patient with chronic lymphocytic leukemia and dysphagia.

J Oncol Pharm Pract. 2021 Jul;27(5):1265-1269. doi: 10.1177/1078155220967440. Epub 2020 Oct 27.

Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo.

Pharmacol Res. 2020 Jan;151:104512. doi: 10.1016/j.phrs.2019.104512. Epub 2019 Nov 12.

引用本文的文献

Extramedullary and extranodal manifestations in chronic lymphocytic leukemia - an update.

Ann Hematol. 2024 Sep;103(9):3369-3383. doi: 10.1007/s00277-024-05854-1. Epub 2024 Jul 25.

本文引用的文献

Remineralization of lytic bone disease in a patient with small lymphocytic lymphoma using ibrutinib.

Br J Haematol. 2017 Jul;178(1):153-155. doi: 10.1111/bjh.14118. Epub 2016 May 12.

Osteolytic lesions occur rarely in patients with B-CLL and may respond well to ibrutinib.

Leuk Lymphoma. 2016 Oct;57(10):2476-80. doi: 10.3109/10428194.2016.1151510. Epub 2016 Feb 25.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Bone Reconstruction in Chronic Lymphocytic Leukemia with Ibrutinib.

作者信息

Koba Yusuke, Kawata Takahito, Tamekane Akira, Watanabe Mitsumasa

机构信息

Department of Hematology, Hyogo Prefectural Amagasaki General Medical Center, Japan.

Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Japan.

出版信息

Intern Med. 2023 Sep 15;62(18):2755-2756. doi: 10.2169/internalmedicine.1334-22. Epub 2023 Feb 8.

DOI:10.2169/internalmedicine.1334-22

PMID:36754402

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10569930/

Abstract

摘要

相似文献

Bone Reconstruction in Chronic Lymphocytic Leukemia with Ibrutinib.

Intern Med. 2023 Sep 15;62(18):2755-2756. doi: 10.2169/internalmedicine.1334-22. Epub 2023 Feb 8.

Prognostic models in chronic lymphocytic leukemia patients receiving ibrutinib therapy: Results of a comparative performance analysis.

Eur J Haematol. 2021 Mar;106(3):425-427. doi: 10.1111/ejh.13548. Epub 2020 Nov 29.

Hepatitis B Virus Reactivation under Ibrutinib Treatment in a Patient with Chronic Lymphocytic Leukemia.

Turk J Haematol. 2020 Aug 28;37(3):208-209. doi: 10.4274/tjh.galenos.2020.2019.0180. Epub 2020 Apr 6.

Ibrutinib as initial therapy in chronic lymphocytic leukemia: A systematic review and meta-analysis.

Eur J Haematol. 2020 May;104(5):512-515. doi: 10.1111/ejh.13387. Epub 2020 Feb 22.

Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study.

Leukemia. 2021 Jan;35(1):235-238. doi: 10.1038/s41375-020-0833-x. Epub 2020 Apr 14.

Intracranial hemorrhage as presentation of chronic lymphocytic leukemia successfully treated with ibrutinib.

Ann Hematol. 2022 Jan;101(1):213-215. doi: 10.1007/s00277-021-04393-3. Epub 2021 Jan 9.

Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes.

Ann Hematol. 2021 Jan;100(1):143-155. doi: 10.1007/s00277-020-04094-3. Epub 2020 Jun 1.

Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia.

Blood. 2021 Feb 25;137(8):1117-1120. doi: 10.1182/blood.2020008608.

Ibrutinib treatment via alternative administration in a patient with chronic lymphocytic leukemia and dysphagia.

J Oncol Pharm Pract. 2021 Jul;27(5):1265-1269. doi: 10.1177/1078155220967440. Epub 2020 Oct 27.

Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo.

Pharmacol Res. 2020 Jan;151:104512. doi: 10.1016/j.phrs.2019.104512. Epub 2019 Nov 12.

引用本文的文献

Extramedullary and extranodal manifestations in chronic lymphocytic leukemia - an update.

Ann Hematol. 2024 Sep;103(9):3369-3383. doi: 10.1007/s00277-024-05854-1. Epub 2024 Jul 25.

本文引用的文献

Remineralization of lytic bone disease in a patient with small lymphocytic lymphoma using ibrutinib.

Br J Haematol. 2017 Jul;178(1):153-155. doi: 10.1111/bjh.14118. Epub 2016 May 12.

Osteolytic lesions occur rarely in patients with B-CLL and may respond well to ibrutinib.

Leuk Lymphoma. 2016 Oct;57(10):2476-80. doi: 10.3109/10428194.2016.1151510. Epub 2016 Feb 25.